logo-theranovir

Breakthrough Solutions for Effective Therapies

Pictogramme tumeur

Oncology

Anti-Cancer Solutions Targeting metastasis, failure and drug resistance

Pictogramme tumeur

Obesity

Preventing cancers by Treating Obesity

Pictogramme tumeur

Viral Infection

Example : targeting adipose tissue HIV reservoir and  Covid19

About us

 

THERANOVIR is a young innovative Health-Tech company of Research and Development of breakthrough therapies in 3 fields of closely related pathologies, Cancer, Obesity and associated metabolic diseases and Infectious Diseases by targeting a platform of signaling pathways regulated by the protein complex NRP-1/OBR, newly discovered by the CEO/CSO Dr. Zakia BELAID-SANDAL (PhD). THERANOVIR benefits from a global and exclusive license from INSERM transfert for the valuation of 2 families of granted patents in Europe, United States and Japan. THERANOVIR filed its own patents in January 2023.

THERANOVIR is developing an immunotherapeutic antibody NOV2 with a unique mode of action through its ability to enter into the nucleus of cancer cells and degrade their DNA in a target-dependent manner based on the NRP-1/OBR complex induced by leptin, without significant genotoxic effect on normal cells and with a very high probability of reactivation of the anti-tumor immune response.

Abstract 3293: Leptin induces breast cancer metastasis through a Neuropilin-1 (NRP-1)/OBR complex 
Zakia Belaid-Choucair(*) et  al .Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): 
AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3293. doi:10.1158/1538-7445.AM2014-3293. * Dr. ZAKIA BELAID-SANDAL (PhD)  ( Widow Choucair)

Theranovir rewards

 

THERANOVIR is a winner of :

  • Lab-SHAKER 2017 (Genopole),
  • Onco-Entrepreneurs 2018 (Cancer Campus, Villejuif),
  • HEC-Challenge+ 2019 (HEC Paris),
  • Ilab 2020 (Ministry of education and research),
  • Innov’up PIA 2021 (Ile-de-France region) competitions.
  • NETVA Start in America 2024

 

Team

Zakia BELAID-SANDAL (PhD)

Co-founder-President / CEO/CSO

17 years of experience in leading and participating in oncology programs in France and abroad

3 co-invented patents

Elie MATTA (PhD)

Assistant Scientific Investigator

PhD in Oncology and Cancer Biology

Co-author of 3 publications in DNA Repair

They support us

Labels

Laureat NETVA 2024

Contact

Head Office

Pépinière, Genopole entreprise
4 rue Pierre-Fontaine
91000 Evry-Courcouronnes

Laboratory R&D

Pavillon de Recherche 1 /Niv4/p401
Institut Gustave Roussy
Cancer Campus
114 Edouard Vaillant
94800 Villejuif

Mail

contact@theranovir.com

Phone

+ 33 1 42 11 60 43

This site is under construction. 

Come back in a few weeks to discover our expertise in details.